Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #71349 on Biotech Values
DewDiligence
01/13/09 3:12 AM
#71410 RE: DewDiligence #71349
Acquired Premium Deal iHub Company Buyer to Market Value Date Reference GNLB GSK 465% $57M 10/08 #msg-33209281 MEMY Roche 319% $50M 11/08 #msg-33787598 KOSN BMY 233% $190M 5/08 #msg-29647147 COLY PFE 167% $165M 11/07 #msg-24600805 EYE ABT 149% **$2.8B 1/09 #msg-34762429 IOMI Intercell 147% $190M 5/08 #msg-29232165 BTRX Stiefel 136% $150M 6/08 #msg-30201906 SGXP LLY 119% $64M 7/08 #msg-30547648 ENCY PFE 118% $350M 2/08 #msg-26978155 TRCA Ipsen 104% $660M 6/08 #msg-29795183 CRY.to MDT 97% $380M 9/08 #msg-32421462 Speedel NVS 94% $880M 7/08 #msg-30588524 MNT JNJ 92% $1.1B 11/08 #msg-33879830 SIRT GSK 85% $620M 4/08 #msg-28705020 TARG MDCO ***72% $42M 1/09 #msg-34774402 Ventana Roche 72% $3.4B 1/08 #msg-30912677 Jerini Shire *71% $520M 7/08 #msg-30452872 Acambis SNY 64% $550M 7/08 #msg-30990498 SCRX Shionogi 61% $1.4B 9/08 #msg-31859174 ALO KG ‡†54% $1.6B 11/08 #msg-33763449 MEDI AZN ‡‡53% $15.2B 4/07 #msg-19020387 MLNM Takeda 53% $8.8B 4/08 #msg-28365383 PCOP LGND ***52% $75M 9/08 #msg-32404474 OMRI JNJ ‡*51% $465M 11/08 #msg-33762745 IMCL LLY †††51% $6.5B 10/08 #msg-32662830 LEVP VPHM ††49% $440M 7/08 #msg-30704409 PHRM CELG 46% $2.9B 11/07 #msg-24645394 IDEV ENDP ***45% $370M 1/09 #msg-34592416 BRL TEVA 42% **$9.0B 7/08 #msg-30792830 MOGN Eisai 39% $3.9B 12/07 #msg-25163775 CGPI Galderma 30% $420M 2/08 #msg-28286522 APPX Fresenius †29% $940M 7/08 #msg-30498388 Zentiva SNY ‡‡26% $2.6B 9/08 #msg-32327005 ARI.to Roche ‡15% $190M 7/08 #msg-30904056 PGLA Avexa ® ® 12/08 #msg-34341452 NTMD Archemix ® ® 11/08 #msg-33656969 NUVO ARCA ® ® 9/08 #msg-32420015 ®Reverse merger with private or non-US company. ‡Number is misleading inasmuch as Arius announced in May 2008 that it was pursued by an unnamed suitor. ‡‡Premium relative to commencement of bidding. ‡†Based on closing price 8/21/08, the day before KG announced initial buyout offer. ‡*Based on 11/20/08 close. †Premium reaches 63% if earn-out met. ††Premium reaches 103% if earn-out met; †††Premium relative to 7/30/08 close, the day before BMY announced first buyout offer. *199% premium to volume-weighted price during preceding 3 months. **Deal value includes assumption of debt. ***Premium and deal value exclude contingent payouts.